




RealRate

PHARMACEUTICAL 2022

Sigilon Therapeutics Inc.
Rank 320 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Sigilon Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sigilon Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Sigilon Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is -216%, being 60% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	126,394
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	34,888
Liabilities, Non-Current	26,988
Other Assets	13,981
Other Compr. Net Income	-10
Other Expenses	0
Other Liabilities	5,333
Other Net Income	-1,675
Property and Equipment	3,994
Research and Development	65,069
Revenues	9,599
Selling, General and Administrative Expense	20,166

Output Variable	Value in 1000 USD
Assets	144,369
Liabilities	67,209
Expenses	85,235
Stockholders Equity	77,160
Net Income	-77,311
Comprehensive Net Income	-77,316
Economic Capital Ratio	-216%